Leonardo DRS wins contract from Department of War

Seeking Alpha - Mon, 03/23/2026 - 15:14

Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M

Seeking Alpha - Mon, 03/23/2026 - 15:14

Aardvark Therapeutics GAAP EPS of -$0.81 beats by $0.02

Seeking Alpha - Mon, 03/23/2026 - 15:12

WisdomTree plans $525M convertible notes offering to fund acquisition

Seeking Alpha - Mon, 03/23/2026 - 15:12

Surrozen GAAP EPS of -$32.37, revenue of $3.47M misses by $0.12M

Seeking Alpha - Mon, 03/23/2026 - 15:11

Bionano Genomics reports Q4 results

Seeking Alpha - Mon, 03/23/2026 - 15:11

Apogee Therapeutics announces $300 million public offering

Seeking Alpha - Mon, 03/23/2026 - 15:07

Veolia Environnement SA (VEOEY) Discusses Integration of ESG as a Value Driver in Financial and Operational Strategy - Slideshow

Seeking Alpha - Mon, 03/23/2026 - 15:01

Envoy Medical GAAP EPS of -$1.23, revenue of $0.02M

Seeking Alpha - Mon, 03/23/2026 - 15:01

Estee Lauder in discussions with Puig for a combination

Seeking Alpha - Mon, 03/23/2026 - 15:01

Gold And Silver: Volatility Reached Extreme Levels, Sell Options

Seeking Alpha - Mon, 03/23/2026 - 14:59

Brookfield Infrastructure raised at Morgan Stanley as leading data center developer

Seeking Alpha - Mon, 03/23/2026 - 14:59

Altria expands distribution of its oral nicotine pouch line

Seeking Alpha - Mon, 03/23/2026 - 14:54

Cheer Holding GAAP EPS of $24.07, revenue of $148.8M

Seeking Alpha - Mon, 03/23/2026 - 14:52

Top performing large-cap stocks YTD as volatility hits markets

Seeking Alpha - Mon, 03/23/2026 - 14:40

Jefferies likes these consumer stocks if the Iran conflict is resolved

Seeking Alpha - Mon, 03/23/2026 - 14:38

The 'Dumb Money' Is Finally Getting Out

Seeking Alpha - Mon, 03/23/2026 - 14:38

Kalshi to ban athletes and politicians from trading on their events

Seeking Alpha - Mon, 03/23/2026 - 14:38

APA upgraded at Barclays on benefit from LNG-linked price contracts

Seeking Alpha - Mon, 03/23/2026 - 14:35

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow

Seeking Alpha - Mon, 03/23/2026 - 14:33

Pages